Ovid Therapeutics price to sales ratio OVID

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 68.9×; Aug 2026
5-year median: 61.1×
5-year range: 0.9× to 168×
Peer median: 1.5×

Ovid Therapeutics' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Aug 2026, at 68.9×.

On the days it had one over the last 5 years, its median was 61.1×, from 0.9× in Jan 2022 to 168× in Apr 2023.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	68.9×	15.3×	71.5×
2025	19.2×	10.4×	108×
2024	109×	109×	163×
2023	168×	91.0×	168×
2022	90.0×	0.9×	110×
2021	1.0×	1.0×	1.1×

Against its peers

Companies in Drug Manufacturers - General nearest Ovid Therapeutics' size, closest first, today.

Company	Price to sales ratio
OVIDOvid Therapeutics	n/m
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
NATRNatures Sunshine Products	0.4×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Ovid Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.